Loading…
QDENGA (TAK-003), a live attenuated tetravalent dengue vaccine from Japan's Takeda, will be India's first approved dengue vaccine.
It received marketing authorisation from the CDSCO in July 2026 for people aged 4 to 60 years.
On 18 September 2026 Takeda and Dr Reddy's Laboratories announced that Dr Reddy's will promote and distribute it in India's private paediatric and adult market.
Takeda retains India's public-market rights and remains responsible for manufacturing and import; availability is expected in the first half of 2027.
India's own candidate, DengiAll, is still in a Phase 3 trial run by ICMR with Panacea Biotec across 19 sites in 18 States and Union Territories.
| Feature | QDENGA (TAK-003) | DengiAll |
|---|---|---|
| Developer | Takeda, Japan | ICMR with Panacea Biotec, India |
| Vaccine type | Live attenuated, tetravalent | Live attenuated, tetravalent, based on the NIH TV003/TV005 strain |
| Status in India | CDSCO marketing authorisation, July 2026 | Phase 3 trial since August 2024, not approved |
| Age group | 4 to 60 years | Not yet approved for any age group |
| Doses | 2 doses, 3 months apart | Single dose, under trial |
| WHO status | Prequalified in 2024 | Not yet applicable |
India's national drug regulator under the Directorate General of Health Services, Ministry of Health and Family Welfare; grants marketing authorisation for new drugs and vaccines
Apex biomedical research body, funding and running the Phase 3 trial of the indigenous DengiAll vaccine with Panacea Biotec
Central programme body for dengue, malaria and other vector-borne disease control, and the source of national dengue case data
The parent law governing the import, manufacture, distribution and sale of drugs and vaccines in India, under which CDSCO acts.
Govern approval of new drugs and vaccines and the conduct of clinical trials, the route both QDENGA's authorisation and DengiAll's Phase 3 trial follow.
GS Paper II > Health: issues relating to health policy; GS Paper III > Science and Technology: developments in biotechnology and vaccines
General Awareness > Science and current affairs: diseases, vaccines and regulators
General Awareness > Current affairs: pharma sector and corporate agreements
Which one of the following statements is not correct?
Answer: Hepatitis B, unlike Hepatitis C, does not have a vaccine.
A vaccine designed to protect against four related strains or serotypes; here DENV-1 to DENV-4.
A vaccine using a weakened form of the pathogen that can replicate enough to provoke immunity without causing the disease.
WHO's assessment that a vaccine meets standards of quality, safety and efficacy, enabling procurement by UN agencies and many countries.
The regulator's permission to market a drug or vaccine in a country for a specified indication and population.